AFYA

AFYA LIMITED (AFYA) — ANALYST NOTE Date: 2026-06-13 Current Price: 14.07

1. Structural Readiness

Conservative Entry: — (Awaiting confirmed breakout) Aggressive/Pre-Breakout Entry: — (Not actionable on setup alone) Breakout Level: — (Not yet established) Current Price: 14.07 Extension: — (No extension data available as no breakout has occurred) ATR Current: 3.9% (Productive / Within historical sweet spot)

2. Thesis Layer

Thesis Status: Tactical / Setup-Led Macro Thesis: None named at this date.

Analysis: There is no named secular macro thesis driving this specific setup as of June 13, 2026. This is a TACTICAL trade driven by the quality of the technical setup and the underlying business fundamentals rather than a broad thematic tailwind. The conviction must be derived strictly from the strength of the "Growth Leader" archetype, the execution of management's guidance, and the structural integrity of the coil. We do not invent a thesis; we judge the name on its ability to execute its stated growth plan within the current market context.

3. Business Analysis

Company Overview: Afya Limited is a prominent medical education provider in Brazil, operating as a holding company with primary revenue derived from its operational subsidiaries. The business model is dual-faceted:

• Undergraduate Education: Tuition fees from medical schools and preparatory courses.
• Digital Health & Continuing Education: Subscription-based platforms for physicians and students.

Key Fundamentals (Source: Earnings Transcript 2026-03-12 & SEC Filing 2026-03-31):

• Revenue & EBITDA Guidance: Management expects 2026 revenue to range between BRL 3.950 billion and BRL 4.100 billion, with adjusted EBITDA anticipated between BRL 1.700 billion and BRL 1.800 billion (excluding post-issuance acquisitions).
• Growth Trajectory: For the 12-month period ended Q4 2025, revenue grew 12% year-over-year to BRL 3.697 billion, while adjusted EBITDA grew over 50% year-over-year to BRL 1.680 billion.
• Operational Expansion: The company secured authorization for 102 additional medical seats in late 2025 (100 at Braganca, 2 at Pato Branco).
• Ecosystem Scale: By end of Q4 2025, the ecosystem encompassed 301,000 physicians and medical students. Underground medical students reached >25,000 (5% growth YoY).
• Digital Engagement: Physicians made over 16.9 million prescriptions using Afya's solutions in the referenced period.
• CapEx: Management expects 2026 CapEx to be between BRL 340 million and BRL 380 million.
• Share Count: As of Dec 31, 2025, there were 55,148,697 Class A and 38,574,134 Class B shares outstanding.

Industry Context: The company operates in the Brazilian medical education sector, heavily influenced by the "Mais Médicos" program. While strong in medicine, the portfolio spans dentistry, nursing, radiology, and other health sciences. The business faces competition from traditional institutions entering the graduate space and rapid technological shifts (AI) in education delivery.

4. Archetype and Conviction

Archetype: Growth Leader Fit Rationale: The name fits the "Growth Leader" archetype due to the demonstrated 12% revenue growth and 50% EBITDA growth, coupled with a clear path to expansion via new seat authorizations and ecosystem scaling. The "margin inflector" aspect is evident in the EBITDA growth outpacing revenue growth, suggesting operating leverage.

Valuation & Financial Spine:

• Forward Consensus EPS: FY1 (2026) at 8.99; FY2 (2027) at 10.45.
• Implied P/E: At a price of 14.07, the stock trades at approximately 1.57x FY1 EPS and 1.35x FY2 EPS. This suggests a valuation that is highly compressed relative to the stated growth rates, assuming the consensus estimates hold.

Conviction Stack:

• Thesis Strength: Low (Tactical only, no macro tailwind).
• Evidence Quality: High. Management has a track record of meeting/exceeding guidance for seven consecutive years (since H2 2018). The financial data is robust and specific.
• Structural Quality: Moderate to High. The ATR of 3.9% indicates healthy volatility without extreme noise. The "Forming" state suggests the market is digesting the strong fundamentals before a potential re-rating.
• Setup Readiness: Partial. The coil is forming, not confirmed. The setup is not yet actionable for a conservative entry.
• Rerating Potential: High. The compression of the P/E ratio relative to 50% EBITDA growth suggests significant rerating potential if the market recognizes the earnings trajectory.

5. Invalidation, Strengthening, and Gaps

What Would Invalidate:

• Management guidance miss for 2026 revenue or EBITDA (breaking the 7-year streak of meeting/exceeding guidance).
• Regulatory reversal of the "Mais Médicos" program or denial of the 102 new seats.

What Would Strengthen:

• A confirmed breakout above the coil resistance level with volume expansion.
• Further acceleration in the digital health subscription base (beyond the 16.9M prescriptions metric).
• Successful integration of AI tools leading to higher retention or pricing power.

Evidence Gaps:

• Breakout Confirmation: No breakout has fired; therefore, the "ATR at breakout" is missing.
• Sector Classification: The specific sector and industry labels are not populated in the setup state, though the business is clearly "Medical Education/Healthcare Services."

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: 50% YoY EBITDA growth to BRL 1.680 billion; 7 consecutive years of meeting/exceeding guidance; Forward P/E of ~1.5x FY1 EPS despite 12% revenue growth; 102 new medical seats authorized for 2026 expansion. Key risks: Regulatory dependency on "Mais Médicos" program; intense competition from traditional institutions in graduate programs; rapid AI disruption altering education delivery models; lack of confirmed technical breakout. Sizing hint: Position size should reflect the "Forming" status; treat as a partial position with room to add on confirmed breakout. Expected path: Management executes on BRL 3.95-4.10B revenue guidance; ecosystem expands to 300k+ users; price consolidates in the forming coil before re-rating higher as earnings catch up to valuation. Expected horizon: 6 to 12 months for the setup to resolve into a confirmed breakout and trend.